Mast To Develop Vepoloxamer (MST-188) In Chronic Heart Failure

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. ANT
3. SPY
4. FFAI
5. FFR
6. META
7. FICO
8. CART
9. LLY
10. TSLA

Go back to Mast To Develop Vepoloxamer (MST-188) In Chronic Heart Failure

Mast Therapeutics (MSTX) to Develop Vepoloxamer (MST-188) to Treat Chronic Heart Failure

March 23, 2015 8:03 AM EDT

Mast Therapeutics (NYSE: MSTX) today announced its plans to develop vepoloxamer (MST-188) for the treatment of patients with chronic heart failure. Encouraged by recently reported nonclinical results and input from experts in the field, the Company expects to begin dosing in a Phase 2 study of vepoloxamer in patients with chronic heart failure in the third quarter of this year.

Wilson S. Colucci M.D., Professor of Medicine and Physiology and Chief of Cardiovascular Medicine at Boston University School of Medicine said: "The results from studies in experimental heart failure are encouraging and support... More